Back to results
US 2024/0180963 A1Published application
Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens
OwnerMartina PIGAZZI, Alessandra BIFFIinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of diagnosing or treating myeloid disorders and acute leukemias by using a tumor specific antigen selected from CD63, CD151, CD72, CD84, CD69, and CD109. Further provided are an antigen binding protein (ABP), an ABP-drug conjugate, and a CAR targeting the tumor specific antigen, and methods for their use.
Claims105
An antigen-binding protein (ABP) that specifically binds a target protein selected from CD63, CD151, CD72, CD84, CD69 and CD109.
A chimeric antigen receptor (CAR) comprising:
- a. an extracellular antigen-binding domain,
- b. a transmembrane domain,
- c. a signaling domain, and
- d. optionally at least one costimulatory domain,
- wherein the extracellular antigen-binding domain specifically binds to a target protein selected from the group consisting of CD63, CD151, CD72, CD84, CD69, and CD109.
2 more elements
A method of diagnosing myeloid disorders (MD) and acute leukemias (AL) in a subject, comprising the step of:
- detecting the presence or level of a tumor specific antigen in a biological sample of the subject, wherein the tumor specific antigen is selected from the group consisting of CD63, CD151, CD72, CD84, CD69, and CD109.
Dependencies are inferred from the claim text.